Literature DB >> 22111602

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.

Kevin C Brown1, Mina C Hosseinipour, Janelle M Hoskins, Ranjit K Thirumaran, Hsiao-Chuan Tien, Ralf Weigel, Jean Tauzie, Ida Shumba, Jatinder K Lamba, Erin G Schuetz, Howard L McLeod, Angela D M Kashuba, Amanda H Corbett.   

Abstract

AIM: Genetic polymorphisms have the potential to influence drug metabolism and vary among ethnic groups. This study evaluated the correlation of genetic polymorphisms with nevirapine pharmacokinetics exposure in Malawians. MATERIALS &
METHODS: CYP450 2B6, 2D6, 3A4 and 3A5, ABCB1 and constitutive androstane receptor and pregnane X receptor, were analyzed for polymorphisms in 26 subjects.
RESULTS: Allele frequencies (variant) were: CYP2B6 514G>T (0.31) CYP2D6*4 (0.02); CYP2D6*17 (0.35); CYP3A4*1B (0.77); CYP3A5*3 (0.25); ABCB1 2677G>T (0.0), ABCB1 3435C>T (0.21), NR1I3 13711152T>C (0.02), NR1I2 44477T>C (0.10), NR1I2 63396C>T (0.33), NR1I2 6-bp indel (del: 0.17). CYP2B6 516G>T (non-wild-type/wild-type) correlated with nevirapine pharmacokinetic parameters; geometric mean ratios (95% CI): 1.75 (1.27-2.40) for area under the concentration time curve (AUC)(0-12 h), 1.58 (1.03-2.42) for C(0), and 0.53 (0.31-0.91) for clearance. In a multivariable model, nevirapine AUC increased by 1.5% per year of age (p < 0.0001), CYP2B6 516 T allele increased AUC by 92% (p < 0.0001), and CYP3A5*3 decreased AUC by 31% (p = 0.0027).
CONCLUSION: Allele frequencies were similar to other sub-Saharan African populations. The T allele for CYP2B6 516 was significantly associated with nevirapine exposure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22111602      PMCID: PMC3292264          DOI: 10.2217/pgs.11.132

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  30 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

Review 2.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

Authors:  L DiAnne Bradford
Journal:  Pharmacogenomics       Date:  2002-03       Impact factor: 2.533

3.  Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection.

Authors:  Naser L Rezk; Richard R Tidwell; Angela D M Kashuba
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-07-05       Impact factor: 3.205

4.  The International HapMap Project.

Authors: 
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

5.  Pharmacogenomics--drug disposition, drug targets, and side effects.

Authors:  William E Evans; Howard L McLeod
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

6.  High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.

Authors:  A I Veldkamp; G J Weverling; J M Lange; J S Montaner; P Reiss; D A Cooper; S Vella; D Hall; J H Beijnen; R M Hoetelmans
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

7.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Authors:  D A Erickson; G Mather; W F Trager; R H Levy; J J Keirns
Journal:  Drug Metab Dispos       Date:  1999-12       Impact factor: 3.922

8.  Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing.

Authors:  Anna-Lena Zackrisson; Bertil Lindblom
Journal:  Eur J Clin Pharmacol       Date:  2003-09-06       Impact factor: 2.953

9.  MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study.

Authors:  David W Haas; Hulin Wu; Haihong Li; Ronald J Bosch; Michael M Lederman; Daniel Kuritzkes; Alan Landay; Elizabeth Connick; Constance Benson; Grant R Wilkinson; Harold Kessler; Richard B Kim
Journal:  J Acquir Immune Defic Syndr       Date:  2003-11-01       Impact factor: 3.731

10.  Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.

Authors:  Theodora E M S de Vries-Sluijs; Jeanne P Dieleman; Dennis Arts; Alwin D R Huitema; Jos H Beijnen; Martin Schutten; Marchina E van der Ende
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more
  15 in total

Review 1.  Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.

Authors:  Andrea Calcagno; Jessica Cusato; Antonio D'Avolio; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

Review 2.  Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.

Authors:  Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2022-06-21

3.  Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.

Authors:  Taimour Langaee; Mohammad H Al-Shaer; Yan Gong; Elizabeth Lima; Sampson Antwi; Anthony Enimil; Albert Dompreh; Hongmei Yang; Wael A Alghamdi; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Infect Genet Evol       Date:  2021-04-08       Impact factor: 3.342

4.  Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life.

Authors:  Alicia Catherine Desmond; Dhayendre Moodley; Catherine A Conolly; Sandra A Castel; Hoosen M Coovadia
Journal:  BMC Pediatr       Date:  2015-03-19       Impact factor: 2.125

Review 5.  Insights into CYP2B6-mediated drug-drug interactions.

Authors:  William D Hedrich; Hazem E Hassan; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2016-08-09       Impact factor: 11.413

Review 6.  Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.

Authors:  Jacinta Nwamaka Nwogu; Qing Ma; Chinedum Peace Babalola; Waheed Adeola Adedeji; Gene D Morse; Babafemi Taiwo
Journal:  AIDS Res Treat       Date:  2016-09-29

7.  ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients.

Authors:  Marelize Swart; Yuan Ren; Peter Smith; Collet Dandara
Journal:  Front Genet       Date:  2012-11-05       Impact factor: 4.599

8.  Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.

Authors:  Laura Dickinson; Masautso Chaponda; Daniel F Carr; Joep J van Oosterhout; Johnstone Kumwenda; David G Lalloo; Munir Pirmohamed; Robert S Heyderman; Saye H Khoo
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

9.  Different frequencies of drug resistance mutations among HIV-1 subtypes circulating in China: a comprehensive study.

Authors:  Hongshuai Sui; Tao Gui; Lei Jia; Wei Guo; Jingwan Han; Yongjian Liu; Zuoyi Bao; Hanping Li; Jingyun Li; Lin Li
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

10.  An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.

Authors:  Marelize Swart; Jonathan Evans; Michelle Skelton; Sandra Castel; Lubbe Wiesner; Peter J Smith; Collet Dandara
Journal:  Front Genet       Date:  2016-01-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.